Abstract:The effects of equipotent glucose-lowering doses of insulinlike growth factor I (IGF-I) and insulin on tracer-determined glucose kinetics and several metabolites were compared in 14 experiments (7 in each group) in fasted, totally depancreatized dogs. This model prevented variations in insulin secretion induced by IGF-I and permitted evaluation of the effects of IGF-I on extrapancreatic glucagon. Steady-state moderate hyperglycemia (9.9 ± 0.2 mM) was maintained by a subbasal intraportal infusion of insulin (1.29 ± 0.17 pmol · kg−1 · min−1). This was continued throughout the experiment, allowing evaluation of IGF-I effects on insulin clearance. Human recombinant IGF-I or insulin was given intravenously as a primed infusion for 90 min, followed by a 50-min recovery period. The dose of IGF-I was a 2.6-nmol/kg bolus plus 57.4 pmol · kg−1 · min−1. The insulin dose required to induce the same plasma glucose decline as IGF-I (44 ± 6 vs. 43 ± 5%, NS) was 9–12 times lower (0.06-nmol/kg bolus + 6.4 ± 0.6 pmol · kg−1 · min−1). However, the mechanism of this decline differed with IGF-I and insulin; glucose production was much less suppressed (25 ± 9 vs. 42 ± 11%, P < 0.001) and glucose utilization was more stimulated (68 ± 18 vs. 38 ± 19%, P < 0.05) with IGF-I. Lactate and pyruvate increased significantly with IGF-I (by 85 ± 28 and 123 ± 83%, respectively) but not with insulin. Glycerol and free-fatty acid levels decreased much less with IGF-I than insulin (29 ± 16 vs. 52 ± 5%, P < 0.05, and 36 ± 10 vs. 56 ± 8%, P < 0.01). β-Hydroxybutyrate, alanine, and glucagon decreased similarly with IGF-I or insulin by 60, 20, and 20%, respectively. Plasma insulin was not affected by IGF-I administration (92.6 ± 8.5 vs. 92.6 ± 10.1 pM). In conclusion, in insulin-infused depancreatized dogs, 1) IGF-I is 8–11% as potent as insulin as a glucose-lowering agent on a molar basis, 2) IGF-I does not affect insulin clearance at doses effective in lowering plasma glucose, and 3) equipotent glucose-lowering doses of IGF-I and insulin have very different effects on both glucose kinetics and lipolysis. This suggests that the IGF-I-insulin potency ratio in vivo is higher in muscle than liver or adipose tissue. Therefore, insulinlike effects of supraphysiological doses of IGF-I can be mediated not only through the insulin but also the IGF-I receptor.

Amylase intrapancreatic infusion delays insulin release during an intravenous glucose tolerance test, proof of acini-islet-acinar interactions

Glp-1, Exendin-4 and C-Peptide Regulate Pancreatic Islet Microcirculation, Insulin Secretion and Glucose Tolerance in Rats

Effect of amylin on secretion of insulin and glucagon in SD rat

In vitro amylase release of preserved pancreas: a simple test to assess the viability of pancreatic allograft during preservation in the pigs

Therapeutic Effect of Ultrasound Interventional Perirenal Catheter-Assisted Early Peripancreatic Lavage of Protease Inhibitor on Severe Acute Pancreatitis in Miniature Pigs

Differential Effects of IGF-I and Insulin on Glucoregulation and Fat Metabolism in Depancreatized Dogs

Alteration of the Pancreatic Endocrine Component in the Early Stage of Acute Necrotic Pancreatitis in Rats

Pancreastatin-like immunoreactivity and insulin are released in parallel from the perfused porcine pancreas

Effect of Amylin on Secretion of Insulin and Glucagon in Rats

Differential Sensitivity of Glycogenolysis and Gluconeogenesis to Insulin Infusions in Dogs

Rapid adaptation of pancreatic exocrine function to short-term alcohol feeding in rats

[Effect of Lipid Infusion on the Function of Islet Beta Cells and Gene Expression of Insulin Signal Transduction System].

Glucotoxicity and Α Cell Dysfunction: Involvement of the PI3K/Akt Pathway in Glucose-Induced Insulin Resistance in Rat Islets and Clonal Αtc1-6 Cells.

1560-P: Combining Glucagon with Insulin Can Lessen the Hypoglycemic Potential of Insulin

1560-P: Inflammation in the Exocrine Pancreas Impairs Insulin Secretion

The Area Postrema Lesions Alter the Inhibitory Effects of Peripherally Infused Pancreatic Polypeptide on Pancreatic Secretion

Cholecystokinin and glucose-induced insulinaemia in dogs with and without pancreatic acinar atrophy

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and During Hyperinsulinemic-Euglycemic Clamp.

Chronic exposure to incretin metabolites GLP-1(9-36) and GIP(3-42) affect islet morphology and beta cell health in high fat fed mice

Kinetics of insulin and C-peptide and estimation of prehepatic insulin secretion rates after intravenous glucose stimulation using arterial versus venous blood sampling in healthy males

Effects of intermittent high glucose on insulin release and insulin sensitivity in diabetic rats